Nicole Fawcett

Rogel Cancer Center researcher Steven J. Katz, M.D., M.P.H., on how genetic testing results impact both the cancer patient and their family.

Why smokers have a higher chance of developing pancreatic cancer and why they tend to have worse outcomes than nonsmokers, according to a new study by University of Michigan Health Rogel Cancer Center.

A new study from University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment. 

A study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer – and offers a potential pathway for new treatments.

As recommendations suggest extending hormone-based breast cancer treatment to 10 years for some patients, a recent study sheds light on whether patients are opting for it.

Researchers from the University of Michigan received a $6 million center grant from the National Institutes of Health to establish the new National Center for Biomedical Imaging and Bioengineering (NCBIB).

University of Michigan Health Rogel Cancer Center scientists identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form. The gene can be indirectly targeted with an existing class of drugs, suggesting a potential treatment strategy for patients with aggressive subtypes of prostate cancer.

The Forbes Institute fosters cross-disciplinary collaboration, encouraging partnerships among faculty from various disciplines across the University of Michigan campus. Learn more about their research into tumor dormancy.

Research by the University of Michigan Health Rogel Cancer Center finds that patients with three of these variants face no extra risk of dying from their cancer.

A specialist outlines some recent advances that have him excited for the future of multiple myeloma treatment.

Andrea Franson, M.D., M.S., received an $800,000 “A” Award grant from Alex’s Lemonade Stand Foundation for Childhood Cancer to translate an approach developed at Rogel Cancer Center into a phase 1 clinical trial for children with high-grade glioma.

Andrea Franson, M.D., M.S., received an $800,000 “A” Award grant from Alex’s Lemonade Stand Foundation for Childhood Cancer to translate an approach developed at Rogel Cancer Center into a phase 1 clinical trial for children with high-grade glioma.

Cuneo appointed associate director for clinical research; Magenau to serve in new assistant director role

The first large scale analysis finds immune checkpoint inhibitors are equally effective in Black and white patients, with Black patients having fewer side effects.

New research has discovered why some cancers don’t respond to immunotherapy treatment: A metabolite transporter within the tumor microenvironment blocks a key type of tumor cell death integral to immune response.